Giacobello Scott M. 4

What Happened Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics, received a grant/award of 38,265 shares on May 14, 2026. The shares were reported at $3.92 per share, for a total reported value of $149,999. This was an award/acquisition (transaction code A), i.e., a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (filing appears timely).
• Shares awarded: 38,265 at $3.92 per share; total reported value $149,999.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnotes/plan details: Filing lists the transaction as an award; no 10b5-1 plan, tax-withholding, or other restrictive footnotes were disclosed in the information provided.

Context Equity awards like this are typically compensation-related and do not directly indicate open-market buying or selling sentiment. For retail investors, purchases or sales in open market transactions can be more informative about an insider’s market view; awards mainly reflect company pay practices and retention/incentive programs.